Sacubitril Hemicalcium
沙库 比曲 半 钙 盐 | Sacubitril Hemicalcium | 1369773-39-6 | In-Domus |
沙库 比曲 钠盐 | 149690-05-1 | In-Domus | |
LCZ-4 | 1426129-50-1 | In-Domus | |
LCZ-7 | 1012341-48-8 | In-Domus | |
LCZ-8 | 1012341-50-2 | In-Domus | |
LCZ-9 | 149690-12-0 | In-Domus |
Background
AHU-377 sal hemicalcium est hemicalcium salis forma AHU-377.Inhibitor neprilysin cum IC50 valore 5 nM [1] est.
AHU-377 et angiotensin II AT1 receptor antagonistam valsartanam componunt LCZ696 in ratione molari 1, 1;LCZ696 receptor angiotensin neprilysin inhibitor est.Potest reducere sanguinem pressura et novum medicamentum ad cordis defectum curationem.AHU-377 pro-medicamentum est, ab enzymatica ethyl niensis in formam activam converti potest LBQ657.Ferunt AHU-377 (30 et 100 mg/kg, PO) effectum antihypertensivum causare posse in modo dosi dependens mures DAHI-SS.Sed in DOCA-sal hypertensiva mures infirma reductionem ostendit [2, 3].
Notae:
[1] Ksander GM, Ghai RD, Jesus R, Diefenbacher CG, Yuan A, Berry C, Sakane Y, Trapani A. Acidum Dicarboxylicum dipeptidum neutrum endopeptidase inhibitores.J Med Chem.1995 May 12;38(10):1689-700.
[2] Voors AA, Dorhout B, van der Meer P. Partes potentiales valsartan + AHU377 (LCZ696) in curatione cordis defectio.Expert Opin Investig Medicamenta.2013 Aug;22(8):1041-7.
[3] Laxminarayan G Hegde, Cecilia Yu, Cheruvu Madhavi et al.Efficacia comparativa de AHU-377, neprilysin inhibitoris potentis, in duobus exemplaribus hypertensionis tomi-dependens.BMC Pharmacology 2011, 11 (Suppl 1): P33.
Chemical structure
Rogatio18Qualitas Constantia Aestimatio inceptis quae probaverunt4, et6incepta approbantes.
Provectus qualitas internationalis administrandi ratio solidum fundamentum venditio posuit.
Qualitas vigilantia percurrit totum vitae cyclum producti, ut qualitatem et therapeuticum effectum curet.
Negotiis professionalibus regularibus turmas sustinet qualitatem postulatorum in applicatione et adnotatione.